Abstract
B-ATF is a nuclear basic leucine zipper protein that belongs to the AP-1/ATF superfamily of transcription factors. Northern blot analysis reveals that the human B-ATF gene is expressed most highly in hematopoietic tissues. Interaction studies in vitro and in vivo show that the leucine zipper of B-ATF mediates dimerization with members of the Jun family of proteins. Chimeric proteins consisting of portions of B-ATF and the DNA binding domain of the yeast activator GAL4 do not stimulate reporter gene expression in mammalian cells, indicating that B-ATF does not contain a conventional transcription activation domain. Jun/B-ATF dimers display similar DNA binding profiles as Jun/Fos dimers, with a bias toward binding TRE (12-O-tetradecanolyphorbol-13-acetate-response element) over CRE (cyclic AMP-response element) DNA sites. B-ATF inhibits transcriptional activation of a reporter gene containing TRE sites in a dose-dependent manner, presumably by competing with Fos for Jun and forming transcriptionally inert Jun/B-ATF heterodimers. Stable expression of B-ATF in C3H10T1/2 cells does not reduce cell viability, but does result in a reduced cellular growth rate when compared to controls. This effect is dominant in the presence of the growth promoting effects of the H-Ras or the v-Fos oncoproteins, since expression of B-ATF restricts the efficiency of focus formation by these transforming agents. These findings demonstrate that B-ATF is a tissue-specific transcription factor with the potential to function as a dominant-negative to AP-1.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
£169.00 per year
only £3.38 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Angel P and Karin M . 1991 Biochim Biophys Acta 1072: 129–157
Aronheim A, Zandi E, Hennemann HS, Elledge SJ and Karin M . 1997 Mol Cell Biol 17: 3094–3102
Bohmann D, Bos TJ, Admon A, Nishimura T, Vogt PK and Tjian R . 1987 Science 238: 1386–1392
Bossy-Wetzel E, Bakiri L and Yaniv M . 1997 EMBO J 16: 1695–1709
Brown PH, Chen TK and Birrer MJ . 1994 Oncogene 9: 791–799
Brown PH, Alani R, Preis LH, Szabo E and Birrer MJ . 1993 Oncogene 8: 877–886
Carrozza ML, Jacobs H, Acton D, Verma I and Berns A . 1997 Oncogene 14: 1083–1091
Chen BPC, Liang G, Whelan J and Hai T . 1994 J Biol Chem 269: 15819–15826
Colotta F, Polentarutti N, Sironi M and Mantovani A . 1992 J Biol Chem 267: 18278–18283
Dang CV, Barrett J, Villa-Garcia M, Resar MS, Kato GJ and Fearon ER . 1991 Mol Cell Biol 11: 954–962
Davenport EA and Taparowsky EJ . 1992 Exp Cell Res 202: 532–540
Davis RL, Weintraub H and Lassar AB . 1987 Cell 51: 987–1000
Dorsey MJ, Tae H-J, Sollenberger KG, Mascarenhas NT, Johansen LM and Taparowsky EJ . 1995 Oncogene 11: 2255–2265
Foletta VC, Segal DH and Cohen DR . 1998 J Leuk Biol 63: 139–152
Fujiwara KT, Kataoka K and Nishizawa M . 1993 Oncogene 8: 2371–2380
Glover JNM and Harrison SC . 1995 Nature 373: 257–261
Grigoriadis AE, Schellander K, Wang Z-Q and Wagner EF . 1993 J Cell Biol 122: 685–701
Hai T and Curran T . 1991 Proc Natl Acad Sci USA 88: 3720–3724
Ham J, Babij C, Whitfield J, Pfarr CM, Lallemand D, Yaniv M and Rubin LL . 1995 Neuron 14: 927–939
Hasegawa H, Utsunomiya Y, Kishimoto K, Tange Y, Yasukawa M and Fujita S . 1996 Biochem Biophys Res Comm 222: 164–170
Hsu J-C, Laz T, Mohn KL and Taub R . 1991 Proc Natl Acad Sci USA 88: 3511–3515
Johnson R, Spiegelman B, Hanahan D and Wisdom R . 1996 Mol Cell Biol 16: 4504–4511
Johnson RS, van Lingen B, Papaioannou VE and Spiegelman BM . 1993 Genes Dev 7: 1309–1317
Karin M, Liu Z-G and Zandi E . 1997 Curr Opin Cell Biol 9: 240–246
Kataoka K, Igarashi K, Itoh K, Fujiwara KT, Noda M, Yamamoto M and Nishizawa M . 1995 Mol Cell Biol 15: 2180–2190
Kataoka K, Noda M and Nishizawa M . 1994 Mol Cell Biol 14: 700–712
Kerppola TK and Curran T . 1991 Curr Opin Struct Biol 1: 71–79
Kerppola TK and Curran T . 1994 Oncogene 9: 675–684
Lemercier C, To RQ, Swanson BJ, Lyons GE and Konieczny SF . 1997 Dev Biol 182: 101–113
Lloyd A, Yancheva N and Wasylyk B . 1991 Nature 352: 635–638
Meyer NP, Johansen LM, Tae H-J, Budde PP, Williams KL and Taparowsky EJ . 1998 Mammal Genome 9: 849–852
Miller AD, Verma IM and Curran T . 1985 J Virol 55: 521–526
Min S, Crider-Miller SJ and Taparowsky EJ . 1994 Cell Growth Differ 5: 563–573
Min S and Taparowsky EJ . 1992 Oncogene 7: 1531–1540
Nakabeppu Y and Nathans D . 1991 Cell 64: 751–759
Olive M, Krylov D, Echlin DR, Gardner K, Taparowsky EJ and Vinson C . 1997 J Biol Chem 272: 18586–18594
Pfarr CM, Mechta F, Spyrou G, Lallemand D, Carillo S and Yaniv M . 1994 Cell 76: 747–760
Ramocki MB, Johnson SE, White MA, Ashendel CL, Konieczny SF and Taparowsky EJ . 1997 Mol Cell Biol 17: 3547–3555
Sambrook J, Fritsch EF and Mainiatis T . 1989 Molecular Cloning A Laboratory Manual Cold Spring Harbor Laboratory Press Cold Spring Harbor, NY
Sassone-Corsi P . 1995 Ann Rev Cell Dev Biol 11: 355–377
Schreiber M, Kolbus A, Piu F, Szabowski A, Möhle-Steinlein U, Tian J, Karin M, Angel P and Wagner EF . 1999 Genes Dev 13: 607–619
Smeal T, Binetruy B, Mercola DA, Birrer M and Karin M . 1991 Nature 354: 494–496
Smeyne RJ, Vendrell M, Hayward M, Baker SJ, Miao GG, Schilling LM, Robertson LM, Curran T and Morgan J . 1993 Nature 363: 166–169
Taparowsky EJ, Suard Y, Fasano O, Shimizu K, Goldfarb M and Wigler M . 1982 Nature 300: 762–764
Teegarden D, Taparowsky EJ and Kent C . 1990 J Biol Chem 265: 6042–6047
Vandel L, Montreau N, Vial E, Pfarr CM, Binetruy B and Castellazzi M . 1996 Mol Cell Biol 16: 1881–1888
Vogt PK and Bos TJ . 1990 Adv Cancer Res 55: 1–35
Wang C-Y, Bassuk AG, Boise LH, Thompson CB, Bravo R and Leiden JM . 1994 Mol Cell Biol 14: 1153–1159
Wang H, Zirong X and Scott RE . 1996 J Cell Biol 135: 1151–1162
Wang X, Peters MA, Utama FE, Wang Y and Taparowsky EJ . 1999 Mol Endocrinol 13: 254–267
Wick M, Lucibello FC and Müller R . 1992 Oncogene 7: 859–867
Wisdom R, Johnson RS and Moore C . 1999 EMBO J 18: 188–197
Xanthoudakis S and Curan T . 1996 Biological Reactive Intermediates V Snyder Ret al eds, Plenum Press New York
Acknowledgements
The authors thank all of the members of the EJ Taparowsky and S Konieczny laboratories at Purdue for their assistance during the course of this study. This work was supported by a grant awarded to EJ Taparowsky from the National Cancer Institute (CA-78264) and a predoctoral fellowship awarded to DR Echlin from the US Army Breast Cancer Research Program.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Echlin, D., Tae, HJ., Mitin, N. et al. B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos. Oncogene 19, 1752–1763 (2000). https://doi.org/10.1038/sj.onc.1203491
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203491
Keywords
This article is cited by
-
siRNA-mediated downregulation of BATF3 diminished proliferation and induced apoptosis through downregulating c-Myc expression in chronic myelogenous leukemia cells
Molecular Biology Reports (2024)
-
RANKL-responsive epigenetic mechanism reprograms macrophages into bone-resorbing osteoclasts
Cellular & Molecular Immunology (2022)
-
The AP-1 transcription factors c-Jun and JunB are essential for CD8α conventional dendritic cell identity
Cell Death & Differentiation (2021)
-
Calycosin suppresses TGF-β-induced epithelial-to-mesenchymal transition and migration by upregulating BATF2 to target PAI-1 via the Wnt and PI3K/Akt signaling pathways in colorectal cancer cells
Journal of Experimental & Clinical Cancer Research (2019)
-
A role for BATF3 in TH9 differentiation and T-cell-driven mucosal pathologies
Mucosal Immunology (2019)